文献速递泌尿生殖MR

验证PI-RADS第二版中的主导序列范式及动态对比增强成像的作用

Validation of the Dominant Sequence Paradigm and Role of Dynamic Contrast-enhanced Imaging in PI-RADS Version 2.
PubMed 文献 · Radiology · 2017-07-19

本研究基于多读者研究数据验证前列腺影像报告和数据系统(PI-RADS)第二版中主导序列范式及动态对比增强(DCE)成像的有限作用,共评估163例患者、检出654个病灶。结果示外周带中弥散加权成像(DW)优于T2加权成像,移行带中T2加权成像与DW成像无显著差异,外周带中DW成像联合DCE成像可提高癌检出概率。

要点

  • PI-RADS 2、3、4、5类病灶的癌检出概率分别为15.7%、33.1%、70.5%、90.7%。
  • 外周带中DW成像优于T2加权成像(OR 3.49 vs 2.45,P = .008)。
  • 外周带中DW评分为3类且DCE阳性的病灶癌检出概率高于DCE阴性者(67.8% vs 40.0%,P = .02)。

核心结论

  • 外周带中DW成像优于T2加权成像;按PI-RADS第二版标准,移行带中T2加权成像与DW成像相比未显示显著差异;外周带中DW评分联合DCE成像可实质性提高癌检出概率。

研究设计与样本

  • 符合HIPAA的回顾性图像解读,数据为前瞻性采集,经当地伦理委员会批准;纳入未治疗患者,行直肠内线圈3-T多参数MR成像;共163例患者,其中110例多参数MR成像后行前列腺切除术、53例多参数MR成像及系统活检均为阴性;9名放射科医师参与,平均每人解读58例患者(范围56-60例);病灶按PI-RADS第二版检出并与全mount前列腺切除病理对照。

诊断标准与关键数值

  • 共检出654个病灶(外周带420个);PI-RADS 2、3、4、5类病灶的癌检出概率分别为15.7%、33.1%、70.5%、90.7%;外周带中DW成像OR 3.49 vs T2加权成像OR 2.45(P = .008);移行带中T2加权成像OR 4.79 vs DW成像OR 3.77(P = .494);外周带中DW评分为3类且DCE阳性的病灶癌检出概率67.8% vs DCE阴性者40.0%(P = .02);外周带中DW成像联合DCE成像的OR为2.0(P = .027),PI-RADS 2、3、4类病灶癌检出概率分别增加15.7%、16.0%、9.2%。

临床应用与阅片要点

  • 作者结论认为外周带中DW成像优于T2加权成像,移行带中T2加权成像与DW成像无显著差异,外周带中DW评分联合DCE成像可提高癌检出概率。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Purpose To validate the dominant pulse sequence paradigm and limited role of dynamic contrast material-enhanced magnetic resonance (MR) imaging in the Prostate Imaging Reporting and Data System (PI-RADS) version 2 for prostate multiparametric MR imaging by using data from a multireader study. Materials and Methods This HIPAA-compliant retrospective interpretation of prospectively acquired data was approved by the local ethics committee. Patients were treatment-naïve with endorectal coil 3-T multiparametric MR imaging. A total of 163 patients were evaluated, 110 with prostatectomy after multiparametric MR imaging and 53 with negative multiparametric MR imaging and systematic biopsy findings. Nine radiologists participated in this study and interpreted images in 58 patients, on average (range, 56-60 patients). Lesions were detected with PI-RADS version 2 and were compared with whole-mount prostatectomy findings. Probability of cancer detection for overall, T2-weighted, and diffusion-weighted (DW) imaging PI-RADS scores was calculated in the peripheral zone (PZ) and transition zone (TZ) by using generalized estimating equations. To determine dominant pulse sequence and benefit of dynamic contrast-enhanced (DCE) imaging, odds ratios (ORs) were calculated as the ratio of odds of cancer of two consecutive scores by logistic regression. Results A total of 654 lesions (420 in the PZ) were detected. The probability of cancer detection for PI-RADS category 2, 3, 4, and 5 lesions was 15.7%, 33.1%, 70.5%, and 90.7%, respectively. DW imaging outperformed T2-weighted imaging in the PZ (OR, 3.49 vs 2.45; P = .008). T2-weighted imaging performed better but did not clearly outperform DW imaging in the TZ (OR, 4.79 vs 3.77; P = .494). Lesions classified as PI-RADS category 3 at DW MR imaging and as positive at DCE imaging in the PZ showed a higher probability of cancer detection than did DCE-negative PI-RADS category 3 lesions (67.8% vs 40.0%, P = .02). The addition of DCE imaging to DW imaging in the PZ was beneficial (OR, 2.0; P = .027), with an increase in the probability of cancer detection of 15.7%, 16.0%, and 9.2% for PI-RADS category 2, 3, and 4 lesions, respectively. Conclusion DW imaging outperforms T2-weighted imaging in the PZ; T2-weighted imaging did not show a significant difference when compared with DW imaging in the TZ by PI-RADS version 2 criteria. The addition of DCE imaging to DW imaging scores in the PZ yields meaningful improvements in probability of cancer detection. © RSNA, 2017 An earlier incorrect version of this article appeared online. This article was corrected on July 27, 2017. Online supplemental material is available for this article.

来源:Radiology,查看原文。版权归原作者所有。

引用

  1. Greer MD, Shih JH, Lay N, et al. Validation of the Dominant Sequence Paradigm and Role of Dynamic Contrast-enhanced Imaging in PI-RADS Version 2. Radiology. 2017. PMID: 28727501. doi:10.1148/radiol.2017161316

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。